Ibutilide

Ibutilide

Error creating thumbnail: File missing
Clinical data
Pregnancy category	C
Routes of administration	Intravenous
ATC code	C01BD05 (WHO)
Pharmacokinetic data
Protein binding	40%
Metabolism	Hepatic oxidation
Elimination half-life	6 hours (2-12 hours)
Excretion	Renal (82%), fecal
Identifiers
IUPAC name N-[4-[4-(ethyl-heptyl-amino)- 1-hydroxy-butyl]phenyl] methanesulfonamide
CAS Number	122647-32-9
PubChem CID	60753
DrugBank	APRD01025
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H36N2O3S
Molar mass	384.578 g/mol

WikiDoc Resources for Ibutilide
Articles
Most recent articles on Ibutilide Most cited articles on Ibutilide Review articles on Ibutilide Articles on Ibutilide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ibutilide Images of Ibutilide Photos of Ibutilide Podcasts & MP3s on Ibutilide Videos on Ibutilide
Evidence Based Medicine
Cochrane Collaboration on Ibutilide Bandolier on Ibutilide TRIP on Ibutilide
Clinical Trials
Ongoing Trials on Ibutilide at Clinical Trials.gov Trial results on Ibutilide Clinical Trials on Ibutilide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ibutilide NICE Guidance on Ibutilide NHS PRODIGY Guidance FDA on Ibutilide CDC on Ibutilide
Books
Books on Ibutilide
News
Ibutilide in the news Be alerted to news on Ibutilide News trends on Ibutilide
Commentary
Blogs on Ibutilide
Definitions
Definitions of Ibutilide
Patient Resources / Community
Patient resources on Ibutilide Discussion groups on Ibutilide Patient Handouts on Ibutilide Directions to Hospitals Treating Ibutilide Risk calculators and risk factors for Ibutilide
Healthcare Provider Resources
Symptoms of Ibutilide Causes & Risk Factors for Ibutilide Diagnostic studies for Ibutilide Treatment of Ibutilide
Continuing Medical Education (CME)
CME Programs on Ibutilide
International
Ibutilide en Espanol Ibutilide en Francais
Business
Ibutilide in the Marketplace Patents on Ibutilide
Experimental / Informatics
List of terms related to Ibutilide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells. Because of its Class III antiarrhythmic activity, there should not be concomitant administration of Class Ia and Class III agents.

Mechanism of action

Unlike most other Class III antiarrhythmic drugs, ibutilide does not produce its prolongation of action potential via blockade of cardiac delayed rectifier of potassium current, nor does it have a sodium-blocking, antiadrenergic, and calcium blocking activity that other Class III agents possess. Thus it is often referred as a “pure” Class III antiarrhythmic drug. It does have action on the slow sodium channel and promotes the influx of sodium through these slow channels. Although potassium current seems to play a role, their interactions are complex and not well understood. Ibutilide’s unique mechanism works by an activation of a specific inward sodium current, thus producing its therapeutic response in which a prolonged action potential increases myocytes’ cardiac refractoriness in case of atrial fibrillation and flutter.

Pharmacokinetics

Absorption

Ibutilide is intravenously administered. However, it has a high first-pass metabolism, which results a poor bioavailability. Individual pharmacokinetic properties are highly viable during the clinical trial.

Distribution

Ibutilide has a relatively large volume of distribution among individual subjects, which is about 11L/kg. Approximately 40% of the drug is bound with plasma albumin of healthy volunteers in a trial. This is also approximately close to patients with atrial fibrillation and flutter.

Metabolism

Ibutilide has a high systemic plasma clearance that closes to the hepatic blood flow (29mL/min/kg). Its metabolic pathway is via liver’s cytochrome P450 system by isoenzymes other than CYP2A4 and CYP2D6 by which the heptyl side chain of ibutilide is oxidized. With eight metabolites are detected in the urine, however, only one is an active metabolite that shares the similar electrophysiologic property of the Class III antiarrhythmic agents. The plasma concentration of this metabolite is only less than 10% of ibutilide.

Excretion

After administration of ibutilide, it is quickly excreted by renal pathway with a half-life of approximately 6 hours. Approximately 82% of a 0.01mg/kg dose is excreted in the urine during the trial. Among those, around 7% is excreted as unchanged drug. The reminder of the drug is excreted in feces (about 19%).

Patient Information

This medication will be given intravenously for your heart disease. You will have continuously ECG monitoring during the infusion and 4 hours after your infusion. Some of the minor side effects are headache and irregular heartbeat. If you experience chest pain and respiratory difficulties, you should report to your doctors immediately.